In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Flexion Therapeutics (FLXN), with a price target of $20. The company’s shares closed yesterday at $9.68, close to its 52-week low of $9.65.
According to TipRanks.com, Byrnes has 0 stars on 0-5 star ranking scale with an average return of -7.4% and a 24.4% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Heron Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Flexion Therapeutics with a $19 average price target, which is a 96.3% upside from current levels. In a report released today, Benchmark Co. also upgraded the stock to Buy with a $19 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.10 and a one-year low of $9.65. Currently, Flexion Therapeutics has an average volume of 607.7K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FLXN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand.
